Technical Analysis for EIGR - Eiger BioPharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
11.55 | -2.61% | -0.31 |
EIGR closed down 2.61 percent on Wednesday, September 18, 2019, on 67 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
Earnings due: Sep 27
*** please verify all earnings dates ***| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Up | Flat |
| See historical EIGR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| 200 DMA Support | Bullish | -2.61% | |
| New Uptrend | Bullish | -2.61% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -2.61% | |
| Upper Bollinger Band Walk | Strength | -2.61% | |
| Inside Day | Range Contraction | -2.61% | |
| Crossed Above 200 DMA | Bullish | -3.19% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -3.19% | |
| Upper Bollinger Band Walk | Strength | -3.19% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a portfolio of late-stage drugs for orphan diseases. It offers Sarasar, which is used for the treatment of hepatitis delta; Exendin that is used for the treatment of hypoglycemia; and Bestatin, which is used for the treatment of pulmonary arterial hypertension and lymphedema. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is based in Palo Alto, California.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Pulmonary Arterial Hypertension Specialty Drugs Hepatitis Pulmonary Hypertension Orphan Diseases Hypoglycemia
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Pulmonary Arterial Hypertension Specialty Drugs Hepatitis Pulmonary Hypertension Orphan Diseases Hypoglycemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more EIGR news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 15.33 |
| 52 Week Low | 8.4 |
| Average Volume | 126,798 |
| 200-Day Moving Average | 11.8026 |
| 50-Day Moving Average | 10.7896 |
| 20-Day Moving Average | 10.9955 |
| 10-Day Moving Average | 11.545 |
| Average True Range | 0.5212 |
| ADX | 26.68 |
| +DI | 27.6498 |
| -DI | 16.0258 |
| Chandelier Exit (Long, 3 ATRs ) | 10.9356 |
| Chandelier Exit (Short, 3 ATRs ) | 11.283600000000001 |
| Upper Bollinger Band | 12.301 |
| Lower Bollinger Band | 9.69 |
| Percent B (%b) | 0.71 |
| BandWidth | 23.746078 |
| MACD Line | 0.3557 |
| MACD Signal Line | 0.262 |
| MACD Histogram | 0.0937 |
| Fundamentals | Value |
|---|---|
| Market Cap | 96.64 Million |
| Num Shares | 8.37 Million |
| EPS | -5.68 |
| Price-to-Earnings (P/E) Ratio | -2.03 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 4.37 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.51 | ||||
| Resistance 3 (R3) | 12.52 | 12.20 | 12.35 | ||
| Resistance 2 (R2) | 12.20 | 11.96 | 12.20 | 12.30 | |
| Resistance 1 (R1) | 11.88 | 11.81 | 11.72 | 11.87 | 12.24 |
| Pivot Point | 11.56 | 11.56 | 11.49 | 11.56 | 11.56 |
| Support 1 (S1) | 11.24 | 11.32 | 11.08 | 11.23 | 10.86 |
| Support 2 (S2) | 10.92 | 11.17 | 10.92 | 10.80 | |
| Support 3 (S3) | 10.60 | 10.92 | 10.75 | ||
| Support 4 (S4) | 10.59 |
